It is a quiet morning at the Centre for Documentation and Information on Medicines (CEDIM) in Burkina Faso. Someone knocks on the door: a drug industry representative barges in complaining. She has visited several hospitals and to her dismay, physicians are challenging use of her company's drug. They continue to prescribe the reference treatment with a favourable benefit-risk balance, as recommended in the latest issue of the local drug bulletin La Lettre du CEDIM. Such visits occur often.